Compare Ginkgo Bioworks Holdings Inc (DNA) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Expedia Group Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.02 (market cap $590.53M), while Expedia Group Inc trades at $267.03 (market cap $31.96B). The key difference: Expedia Group Inc is far larger — about 54.1× Ginkgo Bioworks Holdings Inc's market cap, and Expedia Group Inc pays a 0.66% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | EXPE | |
|---|---|---|
Market Cap | $590.53M | $31.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $301.31 |
52-Week Low | $5.48 | $178.06 |
Enterprise Value | $627.78M | $30.87B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Expedia Group (EXPE) trades at $265.63, down 1.92% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $287.90 implying 8.4% upside. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.96 surpassing expectations of $1.41. Revenue grew to $14.73B in 2025, and net income reached $1.29B, supported by a high gross profit margin of 90.27%. Recent developments include a strategic partnership with Allegiant Travel and upcoming Q2 2026 earnings on August 5, 2026.
The outlook for EXPE is positive, driven by earnings momentum, strategic partnerships, and analyst optimism, but risks include travel sector volatility and high debt levels. The stock presents a growth opportunity with reasonable valuation multiples (P/E 23.47, EV/EBITDA 9.99), though investors should monitor competitive pressures and macroeconomic impacts on travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
